up-to-date with a click!
Update February, 2018
 
Curated by Peter Lansberg,
a Dutch lipidologist and educator, and
reviewed by prof. Philip Barter, Past President of the
International Atherosclerosis Society.

The IAS Statin Newsletter will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

Statin publications February 2018

Other

  1. Chiorescu S, Andercou OA, Grad NO, Mironiuc IA. Intraperitoneal administration of rosuvastatin prevents postoperative peritoneal adhesions by decreasing the release of tumor necrosis factor. Clujul medical (1957) 2018; 91:79-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29440955
  2. Liu Y, Sun L, Chen W et al. Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells. Experimental and therapeutic medicine 2018; 15:1941-1949. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434788
  3. Khan TJ, Ahmed YM, Zamzami MA et al. Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients. Omics : a journal of integrative biology 2018; 22:154-163. http://www.ncbi.nlm.nih.gov/pubmed/?term=29432061

Add on treatments

  1. Honda K, Matoba T, Antoku Y et al. Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion: A Role of Serum Oxysterols. Arterioscler Thromb Vasc Biol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29449331
  2. Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis 2018; 269:219-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407597
  3. Hong SJ, Jeong HS, Ahn JC et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clinical therapeutics 2018; 40:226-241.e224. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402522
  4. Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29397561
  5. Filippatos TD, Panagiotopoulou T, Tzavella E, Elisaf MS. Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418757011. http://www.ncbi.nlm.nih.gov/pubmed/?term=29409336
  6. Gottschall H, Schmoecker C, Hartmann D et al. Aspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29444936
  7. Podzolkov VI, Bragina AE, Osadchiy KK. [A fixed-dose lisinopril+amlodipine+rosuvastatin combination: prospects for its use in patients with hypertension and concomitant dyslipidemia]. Ter Arkh 2017; 89:133-140. http://www.ncbi.nlm.nih.gov/pubmed/?term=29411773

Adherence

  1. Fung V, Graetz I, Reed M, Jaffe MG. Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS One 2018; 13:e0191817. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420613

Atherosclerosis & Imaging

  1. Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis 2018; 269:219-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407597
  2. D'Elia L, La Fata E, Iannuzzi A, Rubba PO. Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clinical and experimental hypertension (New York, N.Y. : 1993) 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420075
  3. Niu H, Wei Z, Zhang Y et al. Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow. Experimental and therapeutic medicine 2018; 15:904-908. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399097
  4. Zhou P, Cao Z, Wang P et al. The Effect of Intensive Statin Therapy on Symptomatic Intracranial Arterial Stenosis. Iranian journal of public health 2018; 47:231-236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445633

Atorvastatin/Rosuvastatin

  1. Franklin JM, Gopalakrishnan C, Krumme AA et al. The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. Am Heart J 2018; 197:153-162. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447776
  2. Taylor BA, Dager AD, Panza GA et al. The effect of high-dose atorvastatin on neural activity and cognitive function. Am Heart J 2018; 197:166-174. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447778
  3. Cheng YY, Kao CL, Lin SY et al. Effect of an increased dosage of statins on spinal degenerative joint disease: a retrospective cohort study. BMJ Open 2018; 8:e017442. http://www.ncbi.nlm.nih.gov/pubmed/?term=29439066
  4. Mittal S, Mohan A, Hadda V et al. Atorvastatin in Bronchiectasis With Chronic Pseudomonas Infection. Chest 2018; 153:579-580. http://www.ncbi.nlm.nih.gov/pubmed/?term=29406230
  5. Lin TK, Liou YS, Lin CH et al. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clinical epidemiology 2018; 10:159-165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403315
  6. Hong SJ, Jeong HS, Ahn JC et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clinical therapeutics 2018; 40:226-241.e224. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402522
  7. Chiorescu S, Andercou OA, Grad NO, Mironiuc IA. Intraperitoneal administration of rosuvastatin prevents postoperative peritoneal adhesions by decreasing the release of tumor necrosis factor. Clujul medical (1957) 2018; 91:79-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29440955
  8. Zidan MF, Ibrahim HM, Afouna MI, Ibrahim EA. In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. Drug development and industrial pharmacy 2018:1-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=29452493
  9. Futatsugi A, Toshimoto K, Yoshikado T et al. Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29440178
  10. Zambrano T, Hirata RDC, Hirata MH et al. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci 2018; 117:55-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=29427701
  11. Niu H, Wei Z, Zhang Y et al. Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow. Experimental and therapeutic medicine 2018; 15:904-908. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399097
  12. Abdel-Daim MM, Abdeen A. Protective effects of rosuvastatin and vitamin E against fipronil-mediated oxidative damage and apoptosis in rat liver and kidney. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018; 114:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=29432839
  13. Mancano MA. ISMP Adverse Drug Reactions: Influenza Vaccine-Induced Stevens-Johnson Syndrome; Vilazodone-Induced Nightmares; Dabigatran-Induced Pustular Eruptions; Neurotoxic and Cardiotoxic Symptoms After Cannabis Concentrate Exposure; Rosuvastatin-Induced Skin Eruption. Hospital pharmacy 2018; 53:15-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434381
  14. Saren G, Yi X, Gong Y. Pleiotropic effects and biological activities of atorvastatin: The sun never set. Int J Cardiol 2018; 254:261. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407106
  15. Zhou P, Cao Z, Wang P et al. The Effect of Intensive Statin Therapy on Symptomatic Intracranial Arterial Stenosis. Iranian journal of public health 2018; 47:231-236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445633
  16. Spiro J, Butts M. Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin? Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29424763
  17. Wong ITY, Huang Y, Zhou Y. Drug Eruption to Rosuvastatin With Recurrence on Simvastatin: A Case Report. Journal of cutaneous medicine and surgery 2018:1203475418756376. http://www.ncbi.nlm.nih.gov/pubmed/?term=29400079
  18. Wang S, Zhang X, Zhai L et al. Atorvastatin Attenuates Cognitive Deficits and Neuroinflammation Induced by Abeta1-42 Involving Modulation of TLR4/TRAF6/NF-kappaB Pathway. Journal of molecular neuroscience : MN 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29417448
  19. Belal TS, Daabees HG, Abdel-Khalek MM et al. New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets. Journal of pharmaceutical analysis 2013; 3:118-126. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403805
  20. Partani P, Verma SM, Gurule S et al. Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(-) electrospray tandem mass spectrometry. Journal of pharmaceutical analysis 2014; 4:26-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403866
  21. Polagani SR, Pilli NR, Gajula R, Gandu V. Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Journal of pharmaceutical analysis 2013; 3:9-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403791
  22. Sharaf El-Din MMK, Salama FMM, Nassar MWI et al. Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations. Journal of pharmaceutical analysis 2012; 2:200-205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403743
  23. Talluri M, Kalyankar A, Ragampeta S. Synchronized separation of atorvastatin-an antihyperlipidemic drug with antihypertensive, antidiabetic, antithrombotic drugs by RP-LC for determination in combined formulations. Journal of pharmaceutical analysis 2012; 2:285-292. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403755
  24. Delgado-Leon TG, Salas-Pacheco JM, Vazquez-Alaniz F et al. Apoptosis in pancreatic beta-cells is induced by arsenic and atorvastatin in Wistar rats with diabetes mellitus type 2. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2018; 46:144-149. http://www.ncbi.nlm.nih.gov/pubmed/?term=29413104
  25. Khan TJ, Ahmed YM, Zamzami MA et al. Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients. Omics : a journal of integrative biology 2018; 22:154-163. http://www.ncbi.nlm.nih.gov/pubmed/?term=29432061
  26. Zhou M, Zheng J, Bi J et al. Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin. Oncology letters 2018; 15:1985-1992. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399200
  27. Mladenovska K, Grapci AD, Vavlukis M et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie 2017; 72:288-295. http://www.ncbi.nlm.nih.gov/pubmed/?term=29441875
  28. Wang Y, Tian Y, Lv P et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie 2017; 72:365-368. http://www.ncbi.nlm.nih.gov/pubmed/?term=29442027

Basic science

  1. Song L, Tao X, Lin L et al. Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy. ACS applied materials & interfaces 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405062
  2. Jang YO, Kim SH, Cho MY et al. Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29428718
  3. Liang H, Feng Y, Cui R et al. Simvastatin protects against acetaminophen-induced liver injury in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 98:916-924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29421861
  4. Pan S, Wu Z, Liu X et al. Simvastatin Ameliorates PAK4 Inhibitor-Induced Gut and Lung Injury. BioMed research international 2017; 2017:8314276. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445744
  5. Huai J, Yang Z, Yi YH, Wang GJ. Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models. Chinese medical journal 2018; 131:461-470. http://www.ncbi.nlm.nih.gov/pubmed/?term=29451152
  6. Zidan MF, Ibrahim HM, Afouna MI, Ibrahim EA. In vitro and in vivo evaluation of cyclodextrin-based nanosponges for enhancing oral bioavailability of atorvastatin calcium. Drug development and industrial pharmacy 2018:1-34. http://www.ncbi.nlm.nih.gov/pubmed/?term=29452493
  7. Hu X, Song C, Fang M, Li C. Simvastatin inhibits the apoptosis of hippocampal cells in a mouse model of Alzheimer's disease. Experimental and therapeutic medicine 2018; 15:1795-1802. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434767
  8. Trogden KP, Battaglia RA, Kabiraj P et al. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018:fj201700663R. http://www.ncbi.nlm.nih.gov/pubmed/?term=29401610
  9. Abdel-Daim MM, Abdeen A. Protective effects of rosuvastatin and vitamin E against fipronil-mediated oxidative damage and apoptosis in rat liver and kidney. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018; 114:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=29432839
  10. Li Y, Liu Q, Sun J et al. Mitochondrial protective mechanism of simvastatin protects against amyloid beta peptide-induced injury in SH-SY5Y cells. International journal of molecular medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29436584
  11. Castellanos-Esparza YC, Wu S, Huang L et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. International journal of oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29436616
  12. Wang S, Zhang X, Zhai L et al. Atorvastatin Attenuates Cognitive Deficits and Neuroinflammation Induced by Abeta1-42 Involving Modulation of TLR4/TRAF6/NF-kappaB Pathway. Journal of molecular neuroscience : MN 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29417448
  13. Yang F, Feng X, Rolfs A, Luo J. Lovastatin promotes myelin formation in NPC1 mutant oligodendrocytes. J Neurol Sci 2018; 386:56-63. http://www.ncbi.nlm.nih.gov/pubmed/?term=29406968
  14. Abdelwahab NS, El-Zeiny BA, Tohamy SI. Two spectrophotometric methods for simultaneous determination of some antihyperlipidemic drugs. Journal of pharmaceutical analysis 2012; 2:279-284. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403754
  15. Belal TS, Daabees HG, Abdel-Khalek MM et al. New simple spectrophotometric method for determination of the binary mixtures (atorvastatin calcium and ezetimibe; candesartan cilexetil and hydrochlorothiazide) in tablets. Journal of pharmaceutical analysis 2013; 3:118-126. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403805
  16. Karanam SR, Katakam P, Chandu BR et al. Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study. Journal of pharmaceutical analysis 2014; 4:286-294. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403892
  17. Partani P, Verma SM, Gurule S et al. Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(-) electrospray tandem mass spectrometry. Journal of pharmaceutical analysis 2014; 4:26-36. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403866
  18. Polagani SR, Pilli NR, Gajula R, Gandu V. Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Journal of pharmaceutical analysis 2013; 3:9-19. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403791
  19. Polagani SR, Pilli NR, Gandu V. High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. Journal of pharmaceutical analysis 2012; 2:206-213. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403744
  20. Ramesh B, Manjula N, Bijargi SR et al. Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC-ESI-MS/MS. Journal of pharmaceutical analysis 2015; 5:161-168. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403928
  21. Sharaf El-Din MMK, Salama FMM, Nassar MWI et al. Validated spectrofluorimetric method for the determination of atorvastatin in pharmaceutical preparations. Journal of pharmaceutical analysis 2012; 2:200-205. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403743
  22. Talluri M, Kalyankar A, Ragampeta S. Synchronized separation of atorvastatin-an antihyperlipidemic drug with antihypertensive, antidiabetic, antithrombotic drugs by RP-LC for determination in combined formulations. Journal of pharmaceutical analysis 2012; 2:285-292. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403755
  23. Wang J, Sun JY, Sha CJ et al. Optimization, validation and application of an assay for the activity of HMG-CoA reductase in vitro by LC-MS/MS. Journal of pharmaceutical analysis 2015; 5:383-388. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403953
  24. De Wolf E, De Wolf C, Richardson A. ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. Oncology letters 2018; 15:1979-1984. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434898
  25. Sekine Y, Nakayama H, Miyazawa Y et al. Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism. Oncology letters 2018; 15:3167-3172. http://www.ncbi.nlm.nih.gov/pubmed/?term=29435052
  26. Richter CP, Young H, Richter SV et al. Fluvastatin protects cochleae from damage by high-level noise. Scientific reports 2018; 8:3033. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445111
  27. Lu Y, Hu Q, Chen L et al. Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3. Xenobiotica 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405807

Cancer

  1. Song L, Tao X, Lin L et al. Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy. ACS applied materials & interfaces 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405062
  2. Li X, Zhou J. Impact of post-diagnostic statin use on ovarian cancer mortality: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29453799
  3. Schairer C, Freedman DM, Gadalla SM, Pfeiffer RM. Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. Breast Cancer Res Treat 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29450675
  4. Trogden KP, Battaglia RA, Kabiraj P et al. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2018:fj201700663R. http://www.ncbi.nlm.nih.gov/pubmed/?term=29401610
  5. Desai P, Wallace R, Anderson ML et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecologic oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29422345
  6. Dawe DE, Ye X, Czaykowski P et al. The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405283
  7. Castellanos-Esparza YC, Wu S, Huang L et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. International journal of oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29436616
  8. Advani AS, Li H, Michaelis LC et al. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia research 2018; 67:17-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407182
  9. Demir C, Anil C, Bozkus Y et al. Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Mildly to Moderately Iodine-Deficient Region? A Prospective Study. Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402848
  10. De Wolf E, De Wolf C, Richardson A. ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. Oncology letters 2018; 15:1979-1984. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434898
  11. Sekine Y, Nakayama H, Miyazawa Y et al. Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism. Oncology letters 2018; 15:3167-3172. http://www.ncbi.nlm.nih.gov/pubmed/?term=29435052
  12. Zhou M, Zheng J, Bi J et al. Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin. Oncology letters 2018; 15:1985-1992. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399200
  13. Caro-Maldonado A, Camacho L, Zabala-Letona A et al. Low-dose statin treatment increases prostate cancer aggressiveness. Oncotarget 2018; 9:1494-1504. http://www.ncbi.nlm.nih.gov/pubmed/?term=29416709

Children

  1. Setia N, Saxena R, Sawhney JPS, Verma IC. Familial Hypercholesterolemia: Cascade Screening in Children and Relatives of the Affected. Indian journal of pediatrics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29450819
  2. Dunger DB, Marcovecchio ML, Deanfield J. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:580-581. http://www.ncbi.nlm.nih.gov/pubmed/?term=29414269
  3. Flynn JT. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:580. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419271
  4. Jonnalagadda VG, Metety VK, Choudhary K. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:579. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419269
  5. Mei ZB, Xiao Y. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:579. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419270

CVD

  1. Honda K, Matoba T, Antoku Y et al. Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion: A Role of Serum Oxysterols. Arterioscler Thromb Vasc Biol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29449331
  2. Galema-Boers AM, Lenzen MJ, Engelkes SR et al. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29398430
  3. Addison D, Lawler PR, Emami H et al. Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer. J Stroke 2018; 20:71-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402065

Endothelium/inflammation

  1. Niu H, Wei Z, Zhang Y et al. Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow. Experimental and therapeutic medicine 2018; 15:904-908. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399097
  2. deFilippi C, Christenson R, Joyce J et al. Statin Effects on Myocardial Fibrosis Markers in People Living with HIV. J Acquir Immune Defic Syndr 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419569

Ethnicity

  1. Chen PH, Wang JS, Lin SY et al. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. Current medical research and opinion 2018:1-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29429368
  2. Setia N, Saxena R, Sawhney JPS, Verma IC. Familial Hypercholesterolemia: Cascade Screening in Children and Relatives of the Affected. Indian journal of pediatrics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29450819
  3. Zhong Z, Wu H, Li B et al. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. Journal of clinical laboratory analysis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29424099
  4. Mladenovska K, Grapci AD, Vavlukis M et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie 2017; 72:288-295. http://www.ncbi.nlm.nih.gov/pubmed/?term=29441875
  5. Wang Y, Tian Y, Lv P et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie 2017; 72:365-368. http://www.ncbi.nlm.nih.gov/pubmed/?term=29442027

FH

  1. Koh KK. Letter by Koh Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". Circulation 2018; 137:639-640. http://www.ncbi.nlm.nih.gov/pubmed/?term=29431666
  2. Kusters DM, Braamskamp M, Langslet G et al. Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)". Circulation 2018; 137:641-642. http://www.ncbi.nlm.nih.gov/pubmed/?term=29431667
  3. Setia N, Saxena R, Sawhney JPS, Verma IC. Familial Hypercholesterolemia: Cascade Screening in Children and Relatives of the Affected. Indian journal of pediatrics 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29450819
  4. Galema-Boers AM, Lenzen MJ, Engelkes SR et al. Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29398430
  5. Chlebus K, Cybulska B, Gruchala M et al. Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practice in Poland. Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399758

Genetics

  1. Alghalyini B, El Shamieh S, Salami A et al. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metab Pers Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420305
  2. Zambrano T, Hirata RDC, Hirata MH et al. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci 2018; 117:55-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=29427701
  3. Filippatos TD, Panagiotopoulou T, Tzavella E, Elisaf MS. Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418757011. http://www.ncbi.nlm.nih.gov/pubmed/?term=29409336
  4. Zhong Z, Wu H, Li B et al. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. Journal of clinical laboratory analysis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29424099
  5. Mladenovska K, Grapci AD, Vavlukis M et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie 2017; 72:288-295. http://www.ncbi.nlm.nih.gov/pubmed/?term=29441875
  6. Wang Y, Tian Y, Lv P et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie 2017; 72:365-368. http://www.ncbi.nlm.nih.gov/pubmed/?term=29442027
  7. Lu Y, Hu Q, Chen L et al. Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3. Xenobiotica 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405807

Guidelines

  1. Etxeberria A, Alcorta I, Perez I et al. Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain. BMC Health Serv Res 2018; 18:93. http://www.ncbi.nlm.nih.gov/pubmed/?term=29422049
  2. Pinho-Gomes AC, Azevedo L, Ahn JM et al. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. J Am Coll Cardiol 2018; 71:591-602. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420954
  3. Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still. J Am Coll Cardiol 2018; 71:794-799. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447742
  4. Cahill MS, Seifried RM, Cheringal JH et al. Implications of New Cholesterol Treatment Guidelines on Statin Utilization, Intensity, and Costs in Active Duty Service Members. Military medicine 2018; 183:e66-e70. http://www.ncbi.nlm.nih.gov/pubmed/?term=29401328

LDL- related parameters

  1. Chen PH, Wang JS, Lin SY et al. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. Current medical research and opinion 2018:1-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29429368
  2. Smit RAJ, Jukema JW, Postmus I et al. Visit-to-visit lipid variability: Clinical significance, effects of lipid-lowering treatment, and (pharmaco)genetics. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29422286
  3. Talbot D, Delaney JAC, Sandfort V et al. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405501

Lifestyle

  1. Einbond LS, Manservisi F, Wu HA et al. A transcriptomic analysis of turmeric: curcumin represses the expression of cholesterol biosynthetic genes and synergizes with simvastatin. Pharmacol Res 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29408497

Meta-analyses

  1. Li R, Wang TJ, Lyu PY et al. Effects of Plasma Lipids and Statins on Cognitive Function. Chinese medical journal 2018; 131:471-476. http://www.ncbi.nlm.nih.gov/pubmed/?term=29451153
  2. D'Elia L, La Fata E, Iannuzzi A, Rubba PO. Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clinical and experimental hypertension (New York, N.Y. : 1993) 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420075
  3. Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29397561
  4. Ma WQ, Zhao Y, Wang Y et al. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials. International urology and nephrology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29404930
  5. Feinkohl I, Winterer G, Pischon T. Associations of dyslipidaemia and lipid-lowering treatment with risk of postoperative cognitive dysfunction: a systematic review and meta-analysis. Journal of epidemiology and community health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29437865
  6. Shen H, Li R, Yan R et al. Adjunctive therapy with statins in schizophrenia patients: A meta-analysis and implications. Psychiatry research 2018; 262:84-93. http://www.ncbi.nlm.nih.gov/pubmed/?term=29427912
  7. To MS, Prakash S, Poonnoose SI, Bihari S. Dose-dependent effects of statins for patients with aneurysmal subarachnoid hemorrhage: meta-regression analysis. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29425980

Metabolic Syndrome - Diabetes

  1. Chen PH, Wang JS, Lin SY et al. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. Current medical research and opinion 2018:1-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29429368
  2. Ray KK, Leiter LA, Muller-Wieland D et al. Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29436756
  3. Nelson AJ, Rochelau SK, Nicholls SJ. Managing Dyslipidemia in Type 2 Diabetes. Endocrinology and metabolism clinics of North America 2018; 47:153-173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407049
  4. Levitt Katz LE, Bacha F, Gidding SS et al. Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. J Pediatr 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29398050
  5. Al-Zakwani I, Al-Mahruqi F, Al-Rasadi K et al. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. Lipids Health Dis 2018; 17:25. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402296
  6. Dunger DB, Marcovecchio ML, Deanfield J. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:580-581. http://www.ncbi.nlm.nih.gov/pubmed/?term=29414269
  7. Flynn JT. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:580. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419271
  8. Jonnalagadda VG, Metety VK, Choudhary K. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:579. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419269
  9. Mei ZB, Xiao Y. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. N Engl J Med 2018; 378:579. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419270

New Treatments

  1. Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis 2018; 269:219-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407597
  2. Ray KK, Leiter LA, Muller-Wieland D et al. Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29436756
  3. Pokrywka GS. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. Postgraduate medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29411675
  4. Kobalava ZD, Villevalde SV, Vorobyeva MA. [Alirocoumab: new perspectives of lipid-lowering therapy]. Ter Arkh 2017; 89:114-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=29411770
  5. Gebauer K, Reinecke H. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. VASA. Zeitschrift fur Gefasskrankheiten 2018:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=29412075

PAD and statins

  1. Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Lipid-lowering treatment in peripheral artery disease. Current opinion in pharmacology 2018; 39:19-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=29413998
  2. Gebauer K, Reinecke H. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. VASA. Zeitschrift fur Gefasskrankheiten 2018:1-12. http://www.ncbi.nlm.nih.gov/pubmed/?term=29412075

Pleiotropic effects of statins

  1. Disbrow D, Seelbach CL, Albright J et al. Statin medications are associated with decreased risk of sepsis and anastomotic leaks after rectal resections. American journal of surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29428155
  2. Jang YO, Kim SH, Cho MY et al. Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis. Biochem Biophys Res Commun 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29428718
  3. Liang H, Feng Y, Cui R et al. Simvastatin protects against acetaminophen-induced liver injury in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 98:916-924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29421861
  4. Cheng YY, Kao CL, Lin SY et al. Effect of an increased dosage of statins on spinal degenerative joint disease: a retrospective cohort study. BMJ Open 2018; 8:e017442. http://www.ncbi.nlm.nih.gov/pubmed/?term=29439066
  5. Wallace A, Albadawi H, Hoang P et al. Statins as a preventative therapy for venous thromboembolism. Cardiovascular diagnosis and therapy 2017; 7:S207-s218. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399524
  6. Mittal S, Mohan A, Hadda V et al. Atorvastatin in Bronchiectasis With Chronic Pseudomonas Infection. Chest 2018; 153:579-580. http://www.ncbi.nlm.nih.gov/pubmed/?term=29406230
  7. Lin TK, Liou YS, Lin CH et al. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clinical epidemiology 2018; 10:159-165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403315
  8. D'Elia L, La Fata E, Iannuzzi A, Rubba PO. Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials. Clinical and experimental hypertension (New York, N.Y. : 1993) 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420075
  9. Chiorescu S, Andercou OA, Grad NO, Mironiuc IA. Intraperitoneal administration of rosuvastatin prevents postoperative peritoneal adhesions by decreasing the release of tumor necrosis factor. Clujul medical (1957) 2018; 91:79-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29440955
  10. Futatsugi A, Toshimoto K, Yoshikado T et al. Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin. Drug metabolism and disposition: the biological fate of chemicals 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29440178
  11. Hu X, Song C, Fang M, Li C. Simvastatin inhibits the apoptosis of hippocampal cells in a mouse model of Alzheimer's disease. Experimental and therapeutic medicine 2018; 15:1795-1802. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434767
  12. Imprialos KP, Stavropoulos K, Doumas M et al. The potential role of statins in treating liver disease. Expert Rev Gastroenterol Hepatol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29431526
  13. Abdel-Daim MM, Abdeen A. Protective effects of rosuvastatin and vitamin E against fipronil-mediated oxidative damage and apoptosis in rat liver and kidney. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2018; 114:69-77. http://www.ncbi.nlm.nih.gov/pubmed/?term=29432839
  14. Carey W. Statin Use In Cirrhosis from Fatty Liver Disease. Hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29443384
  15. Saren G, Yi X, Gong Y. Pleiotropic effects and biological activities of atorvastatin: The sun never set. Int J Cardiol 2018; 254:261. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407106
  16. Ekinci A, Koc S, Erdogan AS, Kesici H. Profilactic role of simvastatin and mitomycin C in tracheal stenosis after tracheal damage: Study in rats. International journal of pediatric otorhinolaryngology 2018; 105:79-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447825
  17. deFilippi C, Christenson R, Joyce J et al. Statin Effects on Myocardial Fibrosis Markers in People Living with HIV. J Acquir Immune Defic Syndr 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29419569
  18. Wang JY, Yao TC, Tsai YT et al. Increased Dose and Duration of Statin Use is Associated with Decreased Asthma-Related Emergency Department Visits and Hospitalizations. The journal of allergy and clinical immunology. In practice 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29426752
  19. Zhong Z, Wu H, Li B et al. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. Journal of clinical laboratory analysis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29424099
  20. Gottschall H, Schmoecker C, Hartmann D et al. Aspirin alone and combined with a statin suppresses eicosanoid formation in human colon tissue. Journal of lipid research 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29444936
  21. Wang S, Zhang X, Zhai L et al. Atorvastatin Attenuates Cognitive Deficits and Neuroinflammation Induced by Abeta1-42 Involving Modulation of TLR4/TRAF6/NF-kappaB Pathway. Journal of molecular neuroscience : MN 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29417448
  22. Yang F, Feng X, Rolfs A, Luo J. Lovastatin promotes myelin formation in NPC1 mutant oligodendrocytes. J Neurol Sci 2018; 386:56-63. http://www.ncbi.nlm.nih.gov/pubmed/?term=29406968
  23. Kreuter M, Costabel U, Richeldi L et al. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration; international review of thoracic diseases 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29414827
  24. Richter CP, Young H, Richter SV et al. Fluvastatin protects cochleae from damage by high-level noise. Scientific reports 2018; 8:3033. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445111
  25. Yildizeli SO, Balcan B, Eryuksel E et al. Influence of Statin Therapy on Exacerbation Frequency in Patients with Chronic Obstructive Pulmonary Disease. Turkish thoracic journal 2017; 18:29-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=29404156
  26. Cohen AJ, Adamsky MA, Nottingham CU et al. Impact of Statin Intake on Kidney Stone Formation. Urology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29421299

Primary Prevention

  1. Ngo-Metzger Q, Gottfredson R. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. American family physician 2017; 96:805-806. http://www.ncbi.nlm.nih.gov/pubmed/?term=29431375
  2. Byrne P, Cullinan J, Murphy C, Smith SM. Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease. BMJ Open 2018; 8:e018524. http://www.ncbi.nlm.nih.gov/pubmed/?term=29439070

Registry data

  1. Disbrow D, Seelbach CL, Albright J et al. Statin medications are associated with decreased risk of sepsis and anastomotic leaks after rectal resections. American journal of surgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29428155
  2. Trivedi LU, Alvarez CA, Mansi IA. Association of Statin Therapy With Risk of Epilepsy in 2 Propensity Score-Matched Cohorts. The Annals of pharmacotherapy 2018:1060028018756650. http://www.ncbi.nlm.nih.gov/pubmed/?term=29400081
  3. Byrne P, Cullinan J, Murphy C, Smith SM. Cross-sectional analysis of the prevalence and predictors of statin utilisation in Ireland with a focus on primary prevention of cardiovascular disease. BMJ Open 2018; 8:e018524. http://www.ncbi.nlm.nih.gov/pubmed/?term=29439070
  4. Cheng YY, Kao CL, Lin SY et al. Effect of an increased dosage of statins on spinal degenerative joint disease: a retrospective cohort study. BMJ Open 2018; 8:e017442. http://www.ncbi.nlm.nih.gov/pubmed/?term=29439066
  5. Li X, Zhou J. Impact of post-diagnostic statin use on ovarian cancer mortality: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29453799
  6. Schairer C, Freedman DM, Gadalla SM, Pfeiffer RM. Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. Breast Cancer Res Treat 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29450675
  7. Lin TK, Liou YS, Lin CH et al. High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clinical epidemiology 2018; 10:159-165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29403315
  8. Izurieta HS, Chillarige Y, Kelman JA et al. Statin use and risks of influenza-related outcomes among older adults receiving standard-dose or high-dose influenza vaccines through Medicare during 2010-2015. Clin Infect Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29438483
  9. Desai P, Wallace R, Anderson ML et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecologic oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29422345
  10. Dawe DE, Ye X, Czaykowski P et al. The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study. International journal of cancer. Journal international du cancer 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405283
  11. Wang JY, Yao TC, Tsai YT et al. Increased Dose and Duration of Statin Use is Associated with Decreased Asthma-Related Emergency Department Visits and Hospitalizations. The journal of allergy and clinical immunology. In practice 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29426752
  12. Addison D, Lawler PR, Emami H et al. Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer. J Stroke 2018; 20:71-79. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402065
  13. Talbot D, Delaney JAC, Sandfort V et al. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405501
  14. Cohen AJ, Adamsky MA, Nottingham CU et al. Impact of Statin Intake on Kidney Stone Formation. Urology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29421299

Renal Disease

  1. Ma WQ, Zhao Y, Wang Y et al. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials. International urology and nephrology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29404930
  2. Cohen AJ, Adamsky MA, Nottingham CU et al. Impact of Statin Intake on Kidney Stone Formation. Urology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29421299 

Reviews

  1. Ngo-Metzger Q, Gottfredson R. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults. American family physician 2017; 96:805-806. http://www.ncbi.nlm.nih.gov/pubmed/?term=29431375
  2. Browndyke JN, Heflin MT. Cognition and brain changes associated with high-dose atorvastatin: A BOLD proposition? Am Heart J 2018; 197:163-165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447777
  3. Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis 2018; 269:219-228. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407597
  4. Wallace A, Albadawi H, Hoang P et al. Statins as a preventative therapy for venous thromboembolism. Cardiovascular diagnosis and therapy 2017; 7:S207-s218. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399524
  5. Zanetti HR, Roever L, Goncalves A, Resende ES. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update. Curr Atheroscler Rep 2018; 20:9. http://www.ncbi.nlm.nih.gov/pubmed/?term=29423787
  6. Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Lipid-lowering treatment in peripheral artery disease. Current opinion in pharmacology 2018; 39:19-26. http://www.ncbi.nlm.nih.gov/pubmed/?term=29413998
  7. Golomb BA, Verden A, Messner AK et al. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29427042
  8. Nelson AJ, Rochelau SK, Nicholls SJ. Managing Dyslipidemia in Type 2 Diabetes. Endocrinology and metabolism clinics of North America 2018; 47:153-173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407049
  9. Carey W. Statin Use In Cirrhosis from Fatty Liver Disease. Hepatology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29443384
  10. Saren G, Yi X, Gong Y. Pleiotropic effects and biological activities of atorvastatin: The sun never set. Int J Cardiol 2018; 254:261. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407106
  11. Pinho-Gomes AC, Azevedo L, Ahn JM et al. Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. J Am Coll Cardiol 2018; 71:591-602. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420954
  12. Tibrewala A, Jivan A, Oetgen WJ, Stone NJ. A Comparative Analysis of Current Lipid Treatment Guidelines: Nothing Stands Still. J Am Coll Cardiol 2018; 71:794-799. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447742
  13. Bravata DM, Myers LJ, Arling G et al. Quality of Care for Veterans With Transient Ischemic Attack and Minor Stroke. JAMA neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29404578
  14. Chlebus K, Cybulska B, Gruchala M et al. Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practice in Poland. Kardiol Pol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399758
  15. Pokrywka GS. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option. Postgraduate medicine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29411675
  16. Kreuter M, Costabel U, Richeldi L et al. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration; international review of thoracic diseases 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29414827
  17. Kobalava ZD, Villevalde SV, Vorobyeva MA. [Alirocoumab: new perspectives of lipid-lowering therapy]. Ter Arkh 2017; 89:114-121. http://www.ncbi.nlm.nih.gov/pubmed/?term=29411770

Safety and side effects

  1. Wang Y, Tian Y, Lv P et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie 2017; 72:365-368. http://www.ncbi.nlm.nih.gov/pubmed/?term=29442027
  2. Samardzic I, Benkovic I, Vrca VB. Incidence of statin-drug interactions in Croatian community pharmacy. Pharmazie 2017; 72:187-191. http://www.ncbi.nlm.nih.gov/pubmed/?term=29442055
  3. Peringat J, Manappallil RG, Karadan U. Rhabdomyolysis: a rare complication of Hashimoto's thyroiditis precipitated by statin therapy. BMJ case reports 2018; 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29440138
  4. Pan S, Wu Z, Liu X et al. Simvastatin Ameliorates PAK4 Inhibitor-Induced Gut and Lung Injury. BioMed research international 2017; 2017:8314276. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445744
  5. Mladenovska K, Grapci AD, Vavlukis M et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie 2017; 72:288-295. http://www.ncbi.nlm.nih.gov/pubmed/?term=29441875
  6. Mancano MA. ISMP Adverse Drug Reactions: Influenza Vaccine-Induced Stevens-Johnson Syndrome; Vilazodone-Induced Nightmares; Dabigatran-Induced Pustular Eruptions; Neurotoxic and Cardiotoxic Symptoms After Cannabis Concentrate Exposure; Rosuvastatin-Induced Skin Eruption. Hospital pharmacy 2018; 53:15-17. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434381
  7. Karunaratne K, Amiras D, Pickering MC et al. Autoimmune necrotising myopathy and HMGCR antibodies. Practical neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29439058
  8. Izurieta HS, Chillarige Y, Kelman JA et al. Statin use and risks of influenza-related outcomes among older adults receiving standard-dose or high-dose influenza vaccines through Medicare during 2010-2015. Clin Infect Dis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29438483
  9. Zhong Z, Wu H, Li B et al. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. Journal of clinical laboratory analysis 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29424099
  10. Wu H, Shang H, Wu J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29397561
  11. Wong ITY, Huang Y, Zhou Y. Drug Eruption to Rosuvastatin With Recurrence on Simvastatin: A Case Report. Journal of cutaneous medicine and surgery 2018:1203475418756376. http://www.ncbi.nlm.nih.gov/pubmed/?term=29400079
  12. Trivedi LU, Alvarez CA, Mansi IA. Association of Statin Therapy With Risk of Epilepsy in 2 Propensity Score-Matched Cohorts. The Annals of pharmacotherapy 2018:1060028018756650. http://www.ncbi.nlm.nih.gov/pubmed/?term=29400081
  13. Spiro J, Butts M. Atorvastatin-Induced Dermatomyositis: Resolution With Change in Statin? Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29424763
  14. Matsubara S, Bokuda K, Asano Y et al. Mitophagy in three cases of immune-mediated necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: ultrastructural and immunohistochemical studies. Neuromuscular disorders : NMD 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402601
  15. Lu Y, Hu Q, Chen L et al. Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3. Xenobiotica 2018:1-8. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405807
  16. Liang H, Feng Y, Cui R et al. Simvastatin protects against acetaminophen-induced liver injury in mice. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018; 98:916-924. http://www.ncbi.nlm.nih.gov/pubmed/?term=29421861
  17. Harrison TN, Hsu JY, Rosenson RS et al. Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management. Cardiovasc Drugs Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29417422
  18. Golomb BA, Verden A, Messner AK et al. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29427042
  19. Filippatos TD, Panagiotopoulou T, Tzavella E, Elisaf MS. Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. Journal of cardiovascular pharmacology and therapeutics 2018:1074248418757011. http://www.ncbi.nlm.nih.gov/pubmed/?term=29409336
  20. Delgado-Leon TG, Salas-Pacheco JM, Vazquez-Alaniz F et al. Apoptosis in pancreatic beta-cells is induced by arsenic and atorvastatin in Wistar rats with diabetes mellitus type 2. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 2018; 46:144-149. http://www.ncbi.nlm.nih.gov/pubmed/?term=29413104
  21. Caro-Maldonado A, Camacho L, Zabala-Letona A et al. Low-dose statin treatment increases prostate cancer aggressiveness. Oncotarget 2018; 9:1494-1504. http://www.ncbi.nlm.nih.gov/pubmed/?term=29416709
  22. Alghalyini B, El Shamieh S, Salami A et al. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metab Pers Ther 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420305

Stroke and CNS

  1. Zhou P, Cao Z, Wang P et al. The Effect of Intensive Statin Therapy on Symptomatic Intracranial Arterial Stenosis. Iranian journal of public health 2018; 47:231-236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445633
  2. Yoshimura S, Uchida K, Morimoto T. Response by Yoshimura et al to Letter Regarding Article, "Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)". Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29438075
  3. Taylor BA, Dager AD, Panza GA et al. The effect of high-dose atorvastatin on neural activity and cognitive function. Am Heart J 2018; 197:166-174. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447778
  4. Scheitz JF, Lees KR, Endres M. Letter by Scheitz et al Regarding Article, "Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute Ischemic Stroke Patient)". Stroke 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29438082
  5. Li R, Wang TJ, Lyu PY et al. Effects of Plasma Lipids and Statins on Cognitive Function. Chinese medical journal 2018; 131:471-476. http://www.ncbi.nlm.nih.gov/pubmed/?term=29451153
  6. Hu X, Song C, Fang M, Li C. Simvastatin inhibits the apoptosis of hippocampal cells in a mouse model of Alzheimer's disease. Experimental and therapeutic medicine 2018; 15:1795-1802. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434767
  7. Feinkohl I, Winterer G, Pischon T. Associations of dyslipidaemia and lipid-lowering treatment with risk of postoperative cognitive dysfunction: a systematic review and meta-analysis. Journal of epidemiology and community health 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29437865
  8. Browndyke JN, Heflin MT. Cognition and brain changes associated with high-dose atorvastatin: A BOLD proposition? Am Heart J 2018; 197:163-165. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447777
  9. To MS, Prakash S, Poonnoose SI, Bihari S. Dose-dependent effects of statins for patients with aneurysmal subarachnoid hemorrhage: meta-regression analysis. World neurosurgery 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29425980
  10. Nelson AJ, Rochelau SK, Nicholls SJ. Managing Dyslipidemia in Type 2 Diabetes. Endocrinology and metabolism clinics of North America 2018; 47:153-173. http://www.ncbi.nlm.nih.gov/pubmed/?term=29407049
  11. Bravata DM, Myers LJ, Arling G et al. Quality of Care for Veterans With Transient Ischemic Attack and Minor Stroke. JAMA neurology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29404578

Triglycerides/HDL

  1. Talbot D, Delaney JAC, Sandfort V et al. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29405501

Trials

  1. Zhou P, Cao Z, Wang P et al. The Effect of Intensive Statin Therapy on Symptomatic Intracranial Arterial Stenosis. Iranian journal of public health 2018; 47:231-236. http://www.ncbi.nlm.nih.gov/pubmed/?term=29445633
  2. Taylor BA, Dager AD, Panza GA et al. The effect of high-dose atorvastatin on neural activity and cognitive function. Am Heart J 2018; 197:166-174. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447778
  3. Ray KK, Leiter LA, Muller-Wieland D et al. Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obes Metab 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29436756
  4. Parish S, Hopewell JC, Hill MR et al. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study. Circulation. Genomic and precision medicine 2018; 11:e001696. http://www.ncbi.nlm.nih.gov/pubmed/?term=29449329
  5. Liu Y, Sun L, Chen W et al. Combined treatment with simvastatin and rapamycin attenuates cardiac allograft rejection through the regulation of T helper 17 and regulatory T cells. Experimental and therapeutic medicine 2018; 15:1941-1949. http://www.ncbi.nlm.nih.gov/pubmed/?term=29434788
  6. Ekinci A, Koc S, Erdogan AS, Kesici H. Profilactic role of simvastatin and mitomycin C in tracheal stenosis after tracheal damage: Study in rats. International journal of pediatric otorhinolaryngology 2018; 105:79-84. http://www.ncbi.nlm.nih.gov/pubmed/?term=29447825
  7. Chen PH, Wang JS, Lin SY et al. Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes. Current medical research and opinion 2018:1-20. http://www.ncbi.nlm.nih.gov/pubmed/?term=29429368
  8. Zambrano T, Hirata RDC, Hirata MH et al. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci 2018; 117:55-61. http://www.ncbi.nlm.nih.gov/pubmed/?term=29427701
  9. Yildizeli SO, Balcan B, Eryuksel E et al. Influence of Statin Therapy on Exacerbation Frequency in Patients with Chronic Obstructive Pulmonary Disease. Turkish thoracic journal 2017; 18:29-32. http://www.ncbi.nlm.nih.gov/pubmed/?term=29404156
  10. Otvos JD, Guyton JR, Connelly MA et al. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. J Clin Lipidol 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29409728
  11. Niu H, Wei Z, Zhang Y et al. Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow. Experimental and therapeutic medicine 2018; 15:904-908. http://www.ncbi.nlm.nih.gov/pubmed/?term=29399097
  12. Levitt Katz LE, Bacha F, Gidding SS et al. Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes. J Pediatr 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29398050
  13. Hong SJ, Jeong HS, Ahn JC et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clinical therapeutics 2018; 40:226-241.e224. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402522
  14. Fung V, Graetz I, Reed M, Jaffe MG. Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS One 2018; 13:e0191817. http://www.ncbi.nlm.nih.gov/pubmed/?term=29420613
  15. Etxeberria A, Alcorta I, Perez I et al. Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain. BMC Health Serv Res 2018; 18:93. http://www.ncbi.nlm.nih.gov/pubmed/?term=29422049

Women and elderly

  1. Noaman S, Al-Mukhtar O, Abramovic S et al. Changes in Statin Prescription Patterns in Patients Admitted to an Australian Geriatric Subacute Unit. Heart, lung & circulation 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29433992
  2. Huai J, Yang Z, Yi YH, Wang GJ. Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models. Chinese medical journal 2018; 131:461-470. http://www.ncbi.nlm.nih.gov/pubmed/?term=29451152
  3. Desai P, Wallace R, Anderson ML et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecologic oncology 2018. http://www.ncbi.nlm.nih.gov/pubmed/?term=29422345
  4. Al-Zakwani I, Al-Mahruqi F, Al-Rasadi K et al. Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study. Lipids Health Dis 2018; 17:25. http://www.ncbi.nlm.nih.gov/pubmed/?term=29402296
 
 

Twitter
IAS Website
For information
You are now on the editors mailing list of the IAS Statin Newsletter.
The IAS Statin Newsletter is part of the IAS News and Literature update service.
 
This activity is supported by an educational grant from Pfizer.